Remedy Meds vs Henry Meds: Evaluating Telehealth GLP-1 Platforms

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Remedy Meds and Henry Meds are two prominent telehealth platforms expanding access to GLP-1 medications for weight management and metabolic health. Both operate as virtual care networks connecting patients with prescribers, yet they employ distinct operational models, pricing structures, and clinical support frameworks that merit careful evaluation.

Patients exploring these platforms often prioritize convenience, cost, and personalized care—yet few understand how clinical governance, pharmacovigilance, and genetic predisposition screening differ across providers. This comparison clarifies what distinguishes these platforms and introduces how precision-wellness approaches, including genetic insights into peptide pathways, can inform your provider choice.

Understanding Remedy Meds and Henry Meds as Telehealth Models

Remedy Meds operates as a direct-to-consumer telehealth platform offering compounded and branded GLP-1 options through a network of licensed prescribers. The platform emphasizes convenience and rapid access, with initial consultations available within days and flexible refill management via mobile app.

Henry Meds, by contrast, positions itself as a medical-first telehealth provider with emphasis on clinical assessment, ongoing provider relationships, and integrated pharmacy support. Henry Meds typically requires more detailed intake documentation and schedules follow-up visits to monitor metabolic markers and medication tolerance.

Clinical Governance and Provider Oversight Comparison

Clinical oversight quality varies between platforms. Remedy Meds contracts with independent prescribers and nurse practitioners across multiple states, offering rapid-access consultations but with variable continuity of care. Henry Meds employs or directly contracts physicians with specialized training in obesity medicine, creating more structured clinical accountability and standardized treatment protocols.

This distinction matters because ongoing provider relationships support medication adjustment, adverse event monitoring, and integration of biomarker data—particularly important in GLP-1 therapy where dose titration and side-effect management require sustained clinical judgment.

Evaluation Factor	Remedy Meds Model	Henry Meds Model
Provider Type	Mixed NP/PA/MD network	Board-certified MDs, obesity specialists
Initial Consultation Timeline	24–48 hours typical	3–7 days typical
Ongoing Follow-Up Structure	Patient-initiated refills	Scheduled clinical reassessment
Pharmacy Integration	Compounded + branded options	Primarily branded medications
Biomarker Monitoring	Optional provider-ordered labs	Integrated metabolic screening

Pricing, Medication Options, and Accessibility

Remedy Meds offers both compounded semaglutide (typically $149/mo) and access to branded options, with transparent tiered pricing. This flexibility appeals to cost-conscious patients and those with insurance coverage gaps, though compounded medications carry different regulatory oversight than FDA-approved branded formulations.

Henry Meds primarily dispenses branded GLP-1s (Ozempic, Wegovy, Mounjaro) through partnered pharmacies, with pricing generally aligned to manufacturer list prices plus platform fees. Insurance acceptance varies; Henry Meds may coordinate with health plans, but out-of-pocket costs can exceed $300–$400/month for branded tirzepatide.

Personalization, Genetic Insights, and Treatment Customization

Neither Remedy Meds nor Henry Meds currently incorporate genetic testing for GLP-1 response predisposition into standard intake workflows. Both rely on traditional medical history, BMI, and metabolic labs to guide medication selection. However, emerging evidence suggests that genetic variants in GLP1R, GIPR, and FTO pathways may influence individual medication efficacy and side-effect tolerance.

For patients seeking deeper personalization, adjunctive genetic testing can provide context about peptide pathway predispositions before provider consultation. This information, combined with clinical assessment, may support more informed medication selection and realistic outcome expectations. PlexusDx's Precision Peptide Genetic Test evaluates variants associated with GLP-1 receptor signaling and metabolic response, offering actionable context for provider conversations without guaranteeing exact medication response.

Safety, Monitoring, and Long-Term Management Frameworks

Safety protocols differ meaningfully. Remedy Meds conducts initial medical screening and provides patient education but relies on patient-reported side effects for ongoing safety assessment. Henry Meds integrates regular clinical visits, labs (lipid panels, glucose, renal function), and provider-monitored dose titration, reducing gaps in adverse event detection.

GLP-1 therapy requires sustained monitoring for pancreatitis risk, dehydration, rapid weight loss complications, and medication interactions. Patients with pre-existing thyroid disease, renal impairment, or history of medullary thyroid carcinoma require stricter provider oversight—a consideration favoring Henry Meds' structured follow-up model. Choose a platform aligned with your medical complexity and preference for ongoing clinical relationships.

How PlexusDx Supports a More Personalized Approach

PlexusDx partners with licensed 503A compounding pharmacies to offer GLP-1 formulations at transparent pricing, with options including Microdose GLP-1 Protocol ($129/month) and GLP-Squared dual-compound ($249/mo). Unlike Remedy Meds or Henry Meds, PlexusDx emphasizes precision-wellness integration—combining clinical consultation with optional genetic screening to inform personalized treatment conversations.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) evaluates predispositions in GLP1R, GIPR, FTO, and MC4R genetic pathways. This testing may help provide context about individual metabolic and receptor-signaling profiles, supporting more informed discussions with healthcare providers about which peptide formulation and dosing strategy align with your genetic predispositions. Testing does not guarantee medication response or predict exact outcomes—it reveals predispositions that should be interpreted with qualified healthcare guidance.

If you're comparing telehealth platforms, consider pairing your provider selection with genetic insight. A PlexusDx genetic test can support your conversation with any prescriber—whether you choose Remedy Meds, Henry Meds, or another platform—by providing data about your peptide pathway predispositions before medication initiation. Combine this with a provider's clinical expertise to develop a more personalized treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How does Remedy Meds differ from Henry Meds in clinical oversight?

Remedy Meds uses a broad prescriber network with rapid initial access and optional ongoing care. Henry Meds employs specialized physicians with structured follow-up visits and integrated metabolic monitoring, offering more consistent clinical governance for ongoing medication management.

Is compounded semaglutide from Remedy Meds equivalent to branded Wegovy?

Compounded and branded semaglutide contain the same active ingredient but differ in manufacturing oversight, quality assurance, and regulatory classification. Compounded formulations are manufactured under 503A pharmacy standards; branded Wegovy is FDA-approved. Both require prescription oversight.

What medication options does PlexusDx offer compared to these platforms?

PlexusDx provides compounded semaglutide ($149/mo), oral semaglutide ($249/mo), compounded tirzepatide ($249/mo), and specialty combinations like Microdose GLP-1 and GLP-Squared. PlexusDx does not offer branded medications but provides lower-cost, accessible alternatives through licensed compounding partners.

Which platform is safer for patients with medical complexity?

Henry Meds' structured clinical visit model and integrated lab monitoring typically suit patients with comorbidities or medication interactions better. Patients with thyroid disease, renal impairment, or polypharmacy should prioritize platforms with regular provider oversight and biomarker assessment.

Can genetic testing help me choose between these platforms?

PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP1R and GIPR pathways, providing context for any provider—Remedy Meds, Henry Meds, or other—to personalize medication selection. Testing supports informed conversations but does not predict exact medication response or replace clinical evaluation.

Related Reading

• Remedy Meds Cost
• Remedy Meds Weight Loss
• Remedy Meds Vs Medvi
• Medvi Vs Remedy Meds

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.